Claudia Rodriguez Capriles

Efficacy and safety of ixekizumab in a phase <scp>III</scp> , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( <scp>IXORA</scp> ‐ <scp>PEDS</scp> )

Amy S. Paller, Marieke M.B. Seyger, Gabriel A. Magariños et al. · British Journal of Dermatology · 2020 · 108 citations · Full text

Medicine, Dermatology, Pharmacotherapy +11

Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)

Andrew Blauvelt, Alexa B. Kimball, Matthias Augustin et al. · British Journal of Dermatology · 2022 · 44 citations · Full text

Medicine, Dermatology, Pharmacotherapy +11

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

Amy S. Paller, Carsten Flohr, Lawrence F. Eichenfield et al. · Dermatology and Therapy · 2023 · 44 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

Kimberley Jackson, Laiyi Chua, Nieves Vélez de Mendizábal et al. · British Journal of Clinical Pharmacology · 2021 · 12 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16